Abstract: Pentavalent antimonials are the first-line drug treatment for American tegumentary leishmaniasis. We report on a patient with chronic renal failure on hemodialysis who presented with cutaneous lesions of leishmaniasis for four months. The patient was treated with intravenous meglumine under strict nephrological surveillance, but cardiotoxicity, acute pancreatitis, pancytopenia, and cardiogenic shock developed rapidly. Deficient renal clearance of meglumine antimoniate can result in severe toxicity, as observed in this case. These side effects are related to cumulative plasma levels of the drug. Therefore, second-line drugs like amphotericin B are a better choice for patients on dialysis. in a patient presenting chronic renal failure (CRF) due to systemic hypertension, on hemodialysis for two years.
American tegumentary leishmaniasis (ATL) is an endemic
parasitic disease that in Brazil is caused mostly by Leishmania (Viannia) braziliensis. 1 Pentavalent antimonials are the first-line drug treatment for ATL. 2, 3 Musculoskeletal pain, headache, nausea, and asthenia are reported as common side effects, and cardiotoxicity, hepatotoxicity, nephrotoxicity, and pancreatitis as rare, and associated with cumulative doses. [4] [5] [6] [7] The authors report severe side effects associated with the use of meglumine antimoniate (Glucantime ® )
in a patient presenting chronic renal failure (CRF) due to systemic hypertension, on hemodialysis for two years.
A 42-year-old male patient from São Paulo State, Brazil, complained of rapidly growing cutaneous lesions on the face for four months. Upon examination we observed an ulcerated and verrucous lesion measuring 10.0 cm on the left malar-zygomatic region associated with similar lesions on the lower lip and right infra-auricular area. (Figures 1 and 2) . Clinical examination was unremark- were severe, particularly cardiotoxicity and pancreatitis. When a patient presents with definitive and total renal failure, the suggestion is to prescribe amphotericin B deoxycholate, which is eliminated mainly by metabolism and is a dialyzable drug, with the liposomal formulation as an alternative.
